Tirzepatid Vs. Retatrutid: Maɓalli Maɓalli Yayi Bayani

Lokacin da mutane suka kwatanta hanyoyin kwantar da hankali na zamani na gaba, sunan daya da ya fi fice shine retatrutide. Sha'awa a cikin wannan kwayar halitta ta girma cikin sauri saboda tana wakiltar babbar hanyar magani fiye da tirzepatide, wanda ke niyya ga masu karɓa guda uku maimakon biyu. A lokaci guda, tirzepatide ya riga ya sami matsayi mai ƙarfi na gaske: FDA-an yarda, samuwa a kasuwa, kuma yana goyan bayan manyan sakamakon asibiti a cikin nau'in ciwon sukari na 2, kiba, da barci mai barci a cikin manya da kiba. Wannan yana haifar da kwatancen kwatance. A gefe guda an kafa agonist dual tare da tabbatar da amfani a yau; A daya bangaren kuma shi ne sabon agonist mai sau uku wanda masu lura da al'amura da yawa ke ganin zai yiwu mataki na gaba a cikin maganin rayuwa. Idan tambayar ita ce wace magani ne ya fi ban sha'awa daga hangen nesa, retatrutide sau da yawa ya fi girma. Idan tambaya ita ce wane magani ne ya fi dacewa a yau, tirzepatide a fili yana kaiwa. Makullin shine fahimtar inda suka bambanta ta hanyar inji, inganci, matsayi na tsari, bayanin martabar aminci, da yuwuwar dogon lokaci.

 

Abin da Tirzepatid yake da kuma dalilin da yasa yake da mahimmanci

Tirzepatid peptide ne mai allura sau ɗaya-mako-mako wanda Lilly ya haɓaka wanda ke aiki azaman agonist dual agonist na masu karɓar GIP da GLP-1. A cikin Amurka, an yarda da tirzepatide azaman Mounjaro don sarrafa glycemic a cikin nau'in ciwon sukari na 2 kuma azaman Zepbound don sarrafa nauyi na yau da kullun a cikin manya tare da kiba, ko kiba tare da aƙalla yanayin da ke da alaƙa da nauyi. Zepbound kuma an amince da FDA don matsakaita-zuwa-tsanani mai hana bacci a cikin manya masu kiba. Wannan matsayi na tsari yana ba da tirzepatide babbar fa'ida mai amfani a kasuwa ta yau.

 

Menene Retatrutid

Retatrutid shima peptide ne wanda ake yi masa allura sau ɗaya kowane mako daga Lilly, amma yana tafiya mataki ɗaya gaba ta hanyar injiniyanci. Maimakon yin aiki akan masu karɓa guda biyu, agonist sau uku ne wanda ke niyya GIP, GLP-1, da masu karɓar glucagon. Lilly ya kwatanta shi a matsayin kwayoyin bincike, kuma daga Maris-Afrilu 2026 ya kasance cikin ci gaban asibiti maimakon amfani da kasuwancin jama'a. Kamfanin ya bayyana a sarari cewa ba a amince da retatrutide ta kowace hukumar gudanarwa ba kuma tana samuwa bisa doka ga mahalarta gwajin asibiti da Lilly ta dauki nauyinsa.

Wannan matsayin bincike yana da mahimmanci, amma baya rage dalilin da yasa kwayoyin ke jan hankali sosai. Ana yin nazarin Retatrutid ba kawai a cikin kiba da nau'in ciwon sukari na 2 ba, har ma a cikin faɗin yanayin cardiometabolic mai faɗi, gami da kafaffen cututtukan zuciya na zuciya, cututtukan hanta da ke da alaƙa da hanta, ƙarancin ƙarancin baya a cikin kiba, da ciwon osteoarthritis na gwiwa da ke hade da kiba ko kiba. Wannan faɗin yana nuna cewa masu bincike suna ganin retatrutide ba kawai a matsayin ɗan takara mai asarar nauyi ba, amma a matsayin dandamali mai fa'ida.

 

Hanyar Aiki: Inda Bambancin Gaskiya Ya Fara

• Tirzepatid a matsayin mai dual agonist

Tirzepatid yana kunna masu karɓar GIP da GLP-1. Wannan aikin dual yana goyan bayan ingantacciyar sigar insulin, raguwar glucose na jini, jinkirta zubar da ciki, rage ci, da rage nauyi mai ma'ana. Ga marasa lafiya da yawa, wannan haɗin ya riga ya yi tasiri sosai. Yana da dalili ɗaya tirzepatide ya zama irin wannan babban suna a cikin kiba da kula da ciwon sukari.

• Retatrutid a matsayin agonist sau uku

Retatrutid yana kunna GIP, GLP-1, da masu karɓar glucagon. Bangaren glucagon shine abin da ya sa ya zama mai ban sha'awa musamman. Yayin da ake danganta glucagon sau da yawa tare da haɓaka glucose na jini, a cikin mahallin magunguna da ya dace kuma yana iya tallafawa ƙarin kashe kuzari da haɓakar mai. Wannan ƙarin hanyar shine babban dalilin da yasa ake yawan magana game da retatrutide a matsayin mai yuwuwa mafi ƙarfi fiye da tirzepatide daga mahangar asarar nauyi.

• Me yasa masana da yawa ke kallon retatrutide a hankali

Daga hangen nesa na kimiyya, retatrutide yana wakiltar ƙirar rayuwa mai faɗi. Tirzepatid ya riga ya kasance babban mataki na gaba daga magunguna guda ɗaya; retatrutide na iya zama ƙoƙari na gaba don faɗaɗa tasirin warkewa. Wannan baya sanya shi 'mafi kyau' kai tsaye a cikin kowane majiyyaci ko kowane yanayin amfani, amma yana bayyana dalilin da yasa galibi ana kallonsa azaman ɗan takara mafi ƙwarewa. Wannan wani ra'ayi ne wanda aka samo asali a cikin bambanci tsakanin niyya mai karɓa biyu da sau uku da kuma siginonin asarar nauyi da aka gani zuwa yanzu.

 

Inganci: Inda Retatrutid Yayi Kama Musamman Mahimmanci

Tirzepatid ya riga ya ba da ingantaccen inganci. A cikin SURMOUNT-1, manya da ke shan Zepbound 15 MG sun rasa matsakaicin 20.9% na nauyin jiki a kan makonni 72, kuma a cikin binciken kai-da-kai SURMOUNT-5, tirzepatide ya nuna 20.2% matsakaicin asarar nauyi a makonni 72 da 13.7% tare da semaglutide. Waɗannan manyan sakamako ne ta kowace ma'auni.

Retatrutid, duk da haka, shine inda tattaunawar ta zama mai ban sha'awa musamman. A cikin sakamakon kiba na kashi 2 na Lilly da aka buga a cikin 2023, retatrutide ya samu har zuwa 24.2% yana nufin rage nauyi a makonni 48 a matsayin ƙarshen ƙarshe na biyu. Kwanan nan, Lilly ya ba da rahoton bayanan ciwon sukari na 3 na nau'in ciwon sukari na 3 yana nuna raguwar A1C na 1.7% zuwa 2.0% a cikin makonni 40 da matsakaicin raguwar nauyin jiki har zuwa 16.8% a kashi na 12 MG. Lilly kuma ya bayyana sakamakon ƙarshen-2025 TRIUMPH-4 a cikin kiba / kiba tare da osteoarthritis na gwiwa, inda retatrutide 12 MG ya ba da 28.7% rage nauyin jiki akan ƙimar inganci, kodayake takamaiman mahallin ya bambanta da mafi girman kiba-kawai kwatancen.

 

Teburin Kwatancen Gefe-da-Geshe

Kashi	Tirzepatid	Retatrutid
Mahimman kalmomin mahimmanci	Matsakaici a cikin wannan labarin	High, kamar yadda mai tasowa mayar da hankali
Makasudin karɓa	GIP + GLP-1	GIP + GLP-1 + glucagon
Halin halin yanzu	FDA-an yarda don nau'in ciwon sukari na 2; an amince da shi azaman Zepbound don kiba / kiba da OSA a cikin manya tare da kiba	Bincike kawai
Samun shiga na yanzu	Amfani da takardar sayan magani don alamun da aka yarda	Gwajin asibiti kawai
Bayanin asarar nauyi	Mai ƙarfi da ingantaccen kasuwanci	Sigina masu ƙarfi ya zuwa yanzu, amma har yanzu ana ci gaba
Bayanan ƙididdiga	Babban ci gaba akan hanyoyin GLP-1-kawai a baya	Sau da yawa ana kallo azaman mataki na gaba
Hadarin wuce gona da iri	Ƙananan, saboda an yarda da shi	Mafi girma, saboda shaida har yanzu tana fitowa
Gabaɗaya hangen nesa	Mafi kyawun zaɓi a yau	Ƙarin ɗan takara na dogon lokaci mai ban sha'awa

Tebur yana sa maƙasudin tsakiya ya fi sauƙin fahimta: tirzepatide shine zaɓi mafi ƙarfi na yau, yayin da retatrutide na iya zama zaɓi mafi ƙarfi mai fuskantar gaba.

 

Tsaro da Haƙuri

Tirzepatid aminci a aikace

Saboda an amince da tirzepatide, yaren tsaro ya fi balaga kuma yana da alama a sarari. Bayanin samfur yana bayanin halayen halayen ciki kamar tashin zuciya, gudawa, amai, maƙarƙashiya, ciwon ciki, da dyspepsia tsakanin batutuwan gama gari. Akwatin gargadi da yaren hana ruwa gudu suma suna cikin lakabin Amurka.

Alamun aminci na Retatrutid ya zuwa yanzu

Retatrutid ya kasance a baya a cikin tsarin rayuwarsa, don haka hoton haƙurinsa bai cika cika ba. Sakamakon Lilly's Fase 3 na ciwon sukari ya ruwaito cewa mafi yawan abubuwan da suka fi dacewa sun hada da gastrointestinal, ciki har da tashin zuciya, zawo, da amai, da farko a lokacin karuwar kashi. Wannan ya yi daidai da abin da likitocin likitoci suka gani a cikin hanyoyin kwantar da hankali na incretin, amma retatrutide har yanzu yana buƙatar ƙarin lokaci da manyan bayanai kafin a fahimci cikakken bayaninsa.

Me yasa wannan yana da mahimmanci a kwatanta

Kwayoyin halitta na iya kama da ƙarfi kuma har yanzu yana buƙatar ƙarin taka tsantsan. Wannan shine batun daidaitawa a nan. Retatrutid na iya zama mai ban sha'awa ta hanyar injiniya kuma yana iya tabbatar da mafi inganci ga wasu marasa lafiya, amma tirzepatide a halin yanzu yana da fa'idar ingantaccen tsarin aminci da alamar alama.

 

Wanene Zai Iya Fi son Tirzepatid, kuma Wanene Ke Kallon Retatrutid?

Ga marasa lafiya da likitocin da ke yanke shawara a yau , tirzepatide shine amsar da ta dace saboda an yarda da shi, an tsara shi, kuma yana goyan bayan lakabi na yau da kullum. Yana da zaɓi don amfani da ainihin duniya a yanzu.

Ga masu bincike, masu lura da bututun mai, da masu karatu masu sha'awar inda maganin rayuwa ke tafiya, retatrutide na iya zama mafi kyawun kwayoyin halitta saboda abubuwa uku:

1. Faɗin tsari ta hanyar ɓacin rai sau uku.

2. Ƙaƙƙarfan sigina na asarar nauyi a cikin lokaci 2 da ƙarfafa sabuntawa na Mataki na 3.

3. Faɗin sawun ci gaba na dabarun haɓakawa a cikin abubuwan da ke da alaƙa da kiba da yanayin cardiometabolic.

Don haka yayin da ba daidai ba ne a ce retatrutide ya riga ya zama mafi kyawun magani na duniya, yana da kyau a ce retatrutide shine ɗan takarar da mutane da yawa ke sa ido sosai a nan gaba. Wannan tsarin yana ɗaukar alƙawarinsa da iyakokinsa na yanzu.

 

Neman Gaba: Shin Retatrutid Zai Iya Samun Tirzepatid?

Akwai jerin jerin gwaji na hukuma don binciken kai tsaye kwatanta retatrutide da tirzepatide a cikin manya masu kiba, wanda ke nuna yadda tsakiyar wannan kwatancen ya zama. Babban shirin retatrutide na Lilly shima yana ci gaba ta hanyar nazarin TRIUMPH da TRANSCEND da yawa. A wasu kalmomi, tambayar ba ita ce ko retatrutide yana da mahimmanci; shi ne ko bayanansa na gaba za su yi ƙarfi sosai don tabbatar da canjin warkewa mafi girma.

Idan sakamakon ci gaba ya ci gaba da ƙarfafa asarar nauyi mai ƙarfi da fa'idodin rayuwa mai fa'ida, retatrutide zai iya zama ɗayan mahimman hanyoyin kwantar da kiba na gaba a cikin haɓakawa.

 

Tunani Na Karshe

Lokacin kwatanta tirzepatide da retatrutide, mafi kyawun ƙarshe ba shine wanda ya riga ya ci nasara ba, amma sun mamaye wurare daban-daban a cikin yanayin jiyya. Tirzepatid shine mafi kafaffen zaɓi, wanda aka goyi bayan amincewa, samuwa, da yawan amfani da asibiti. Retatrutid shine dan takarar da ya fi neman gaba, yana goyan bayan tsarin agonist mai fa'ida sau uku da kuma ƙarin bayanai masu ban sha'awa waɗanda ke ba da shawarar cewa zai iya tura filin gaba idan sakamakon gaba ya ci gaba da riƙewa. Daga hangen nesanmu, shine ainihin dalilin da ya sa retatrutide ya cancanci kulawa sosai. yana iya zama da amfani a bincika Cocer Peptides Co., Ltd. don ƙarin bayani. 

 

FAQ

1. An yarda da tirzepatide yayin da retatrutide ba a yarda ba?

Ee. Tirzepatid shine FDA-an yarda don nau'in ciwon sukari na 2 kamar Mounjaro da kuma kiba / kiba da OSA a cikin manya tare da kiba kamar Zepbound, yayin da retatrutide ya ci gaba da bincike.

2. Me yasa aka dauki retatrutide ya fi ci gaba a kimiyyance?

Saboda yana kai hari ga masu karɓa guda uku-GIP, GLP-1, da glucagon-maimakon biyu, waɗanda zasu iya haifar da fa'idar tasirin rayuwa da yuwuwar sakamako mai ƙarfi-asara.

3. Shin retatrutide ya nuna ƙarfin asarar nauyi fiye da tirzepatide?

Sigina na farko da na tsakiya suna da ƙarfi sosai, gami da sakamakon kiba na kashi 2 har zuwa 24.2% yana nufin rage nauyi a makonni 48 kuma daga baya sabuntawar gwaji tare da ma fi girman inganci-ƙididdigar ƙima a cikin wasu al'ummomi, amma kwatancen gwaji har yanzu yana buƙatar taka tsantsan.

4. Shin masu karatu za su iya siyan retatrutide bisa doka yanzu?

A'a. Lilly ta ce retatrutide yana samuwa a bisa doka kawai ta hanyar gwaje-gwaje na asibiti, kuma FDA ta gargadi masu amfani da su kada su sayi kayayyakin da ba a yarda da su ba da aka sayar a matsayin bincike-amfani da GLP-1 kwayoyi.